<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00069823</url>
  </required_header>
  <id_info>
    <org_study_id>157</org_study_id>
    <secondary_id>U01HL072968</secondary_id>
    <nct_id>NCT00069823</nct_id>
  </id_info>
  <brief_title>Study of Acid Reflux in Asthma</brief_title>
  <official_title>The Study of Acid Reflux in Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Lung Association Asthma Clinical Research Centers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if subjects with symptomatic asthma who are
      assigned to treatment with a proton pump inhibitor (PPI) drug such as Nexium have fewer
      asthma attacks than similar subjects assigned to placebo treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Gastroesophageal reflux (GERD) is frequent in asthmatics with poor asthma control, often
      occurs without symptoms, and can induce bronchoconstriction. Poorly controlled asthmatics are
      often treated for GERD with drugs that suppress gastric acid, but this treatment is expensive
      and the benefit of such treatment is not established. Proton pump inhibitors are a relatively
      new class of medications that provide highly effective treatment for GERD and associated
      problems. This success has led many doctors to begin PPI treatment in their asthma patients
      in an attempt to achieve better asthma control.

      DESIGN NARRATIVE:

      The randomized, placebo-controlled trial will enroll 400 asthmatics, ages 18 or older, who
      have poor asthma control on inhaled steroids, defined on the basis of excessive
      bronchodilator use, nocturnal awakenings, or frequent exacerbations. Participants will be
      randomly assigned to treatment with either a proton pump inhibitor, esomeprazole (Nexium) 40
      mg twice a day, or matching placebo. The presence, severity, and temporal relationship of
      GERD to asthma symptoms will be documented with 24 hour ambulatory esophageal potential
      Hydrogen (pH) probe monitoring, but participants will be enrolled irrespective of the
      severity of GERD. The primary outcome measure is the proportion of participants who have
      exacerbations of asthma within a 6-month period defined by asthma diaries and interviews.
      Secondary outcome measures include asthma symptom and control scores, asthma-specific and
      generic health-related quality of life, GERD symptoms, health care use, pulmonary function,
      and airways reactivity. Pre-specified subgroup analyses will be conducted to determine if
      there are clinical or demographic characteristics that predict benefit from treatment of GERD
      in asthma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Episodes of Poor Asthma Control (EPAC) From Diary Cards, According to Definition That Did Not Include Use of Beta-agonists as a Criterion</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>Episodes of poor asthma control was defined as any one of the following: 2 consecutive days with a drop in peak flow &gt;=30% of baseline; urgent care for asthma; or new use of oral corticosteroids for asthma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exacerbation Components: &gt;=30% Drop in Peak Expiratory Flow on 2 Consecutive Days</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbation Components: Urgent Care Visit</measure>
    <time_frame>Measured at Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbation Components: New Use of Oral Corticosteroids</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Episodes, According to Definition That Included Increased Use of Beta-agonists</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue Medications</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>Increase in the use of rescue meds by 4 or more uses on a particular day above the average uses during the run-in period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night Awakening</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>Rate of awakening at night because of asthma symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function: Change in Prebronchodilator FEV1</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>Mean change in pre-bronchodilator FEV1 - forced expiratory volume in 1 second; a measure of pulmonary function. The treatment effect is the difference in the mean change in between the groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function: Change in Prebronchodilator Forced Vital Capacity</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>Pulmonary function measured by mean change in Prebronchodilator forced vital capacity from baseline to 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function: Change in Peak Flow Rate</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>Mean change from baseline to 24 weeks in the peak flow rate - how forceful patient can blow out air</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function: Change in PC20</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>Mean Change in the dose of methacholine that results in a 20% drop in FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Juniper Asthma Control Score(JACQ)</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>Mean change. Scores on the JACQ range from 0 to 6, with lower scores indicating better asthma control and 0.5 as the minimal clinically important difference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Asthma Symptom Utility Index (ASUI)</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>Mean change. Scores on the ASUI range from 0 to 1, with higher scores indicating less severe asthma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ)</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>Mean change. Scores on the Mini-Asthma Quality of Life Questionnaire (mini-AQLQ)range from 1 to 7, with higher scores indicating better quality of life and 0.5 as the minimal clinically important difference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Medical Outcomes Study Short-Form 36 Score Quality of Life Score: Physical Component</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>Mean change. Scores on the Medical Outcomes Study Short-Form 36 range from 1 to 100, with higher scores indicating better quality of life and 5 as the minimal clinically important difference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Medical Outcomes Study Short-Form 36 Quality of Life Score: Mental Component</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>Mean change. Scores on the Medical Outcomes Study Short-Form 36 range from 1 to 100, with higher scores indicating better quality of life and 5 as the minimal clinically important difference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gastric Symptoms: Gastroesophageal Reflux Disease Symptom Assessment Scale Score</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>Mean change. The Gastroesophageal Reflux Disease Symptom Assessment Scale score ranges from 0 to 3, with lower numbers indicating less distress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Gastric Symptoms: No. of Symptoms</measure>
    <time_frame>Baseline to 24 Weeks</time_frame>
    <description>Mean change</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">403</enrollment>
  <condition>Asthma</condition>
  <condition>Lung Diseases</condition>
  <condition>Lung Diseases, Obstructive</condition>
  <arm_group>
    <arm_group_label>Esomeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proton pump inhibitor of gastric acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for esomeprazoe</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Proton pump inhibitor 40 mg orally twice daily</description>
    <arm_group_label>Esomeprazole</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo proton pump inhibitor</intervention_name>
    <description>Placebo proton pump inhibitor</description>
    <arm_group_label>Placebo for esomeprazoe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The general goal of patient selection is to enroll patients for whom asthma physicians
             might prescribe GERD treatment, but where there is uncertainty whether it might be
             effective.

          -  Age 18 or older

          -  Physician diagnosed asthma

          -  If amount of air expired in the first second during a forced expiratory maneuver
             (FEV1) is greater than or equal to 70% predicted normal pre-bronchodilator:
             demonstrate methacholine 20% from post-diluent baseline (PC20). PC20 less than 16
             mg/ml during Visit 1

          -  If FEV1 less than 70% and greater than or equal to 50% predicted normal
             pre-bronchodilator: demonstrate 12% reversibility during Visit 1 or within past 12
             months

          -  Currently on stable dose of daily inhaled steroids for asthma control, i.e., inhaled
             corticosteroid equivalent to 400 ug/day of fluticasone44 or greater for 8 weeks or
             longer

          -  Poor asthma control: Either of the following; a score of 1.5 or greater on the Juniper
             Asthma Control Questionnaire; two or more episodes of asthma symptoms in the past 12
             months with each episode requiring at least one of the following: an emergency
             department visit, unscheduled physician visit, prednisone course, hospitalization

          -  Non-smoker for 6 months or longer

          -  Less than 10 pack/year smoking history

        Exclusion Criteria:

          -  Surgery: Previous anti-reflux or peptic ulcer surgery

          -  Pulmonary function: FEV1 less than 50% predicted normal pre-bronchodilator

          -  GERD Symptoms: Severe reflux constituting a clinical indication for treatment with a
             PPI or H2 blocker, typically two or more episodes per week of heartburn requiring
             antacids

          -  Other major chronic illnesses; conditions which in the judgment of the Study Physician
             would interfere with participation in the study, e.g., non-skin cancer, endocrine
             disease, coronary artery disease, congestive heart failure, stroke, severe
             hypertension, Type 1 insulin dependent diabetes mellitus, renal failure, liver
             disorders, immunodeficiency states, major neuropsychiatric disorder

          -  Medication use: Anti-reflux medication (proton pump inhibitors or H2 blockers) within
             1 month Theophylline, azoles, iron, anti-coagulants, insulin (for Type I diabetes),
             digitalis, any investigative drugs within 1 month

          -  Drug allergy: Previous adverse effects from proton pump inhibitors or methacholine
             challenge

          -  Females of childbearing potential: Pregnant or lactating, unwilling to practice an
             adequate birth control method (abstinence, combination barrier and spermicide, or
             hormonal)

          -  Inability or unwillingness to provide consent

          -  Inability to perform baseline measurements

          -  Completion of less than 10 of the last 14 days of screening period diary entry

          -  Inability to be contacted by telephone

          -  Intention to move out of the area within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Wise</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Childrens Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University ACRC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSUHSC Pulmonary Critical Care</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of MO Kansas City School of Medicine</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63310-1093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore-LIJ Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson Hospital Pulmonary Lab</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-3411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern New England Consortium</name>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <zip>05446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2003</study_first_submitted>
  <study_first_submitted_qc>October 2, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2003</study_first_posted>
  <results_first_submitted>May 14, 2010</results_first_submitted>
  <results_first_submitted_qc>September 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2012</results_first_posted>
  <last_update_submitted>December 17, 2012</last_update_submitted>
  <last_update_submitted_qc>December 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins Bloomberg School of Public Health</investigator_affiliation>
    <investigator_full_name>Robert Wise</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Heartburn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The planned enrollment was for 400 participants, 403 participants actually were enrolled and randomized in the trial. It is not uncommon for clinical trials not to exactly meet the sample size stated in the protocol.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>40 mg of placebo twice daily</description>
        </group>
        <group group_id="P2">
          <title>Esomeprazole</title>
          <description>40 mg of esomeprazole twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="199">The design was for 200 participants per group, the study did not exactly meet the design.</participants>
                <participants group_id="P2" count="203">The design was for 200 participants per group, the study did not exactly meet the design.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="193"/>
                <participants group_id="P2" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not have follow-up diary cards</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>40 mg of placebo twice daily</description>
        </group>
        <group group_id="B2">
          <title>Esomeprazole</title>
          <description>40 mg of esomeprazole twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="199"/>
            <count group_id="B2" value="203"/>
            <count group_id="B3" value="402"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="13"/>
                    <measurement group_id="B2" value="42" spread="13"/>
                    <measurement group_id="B3" value="42" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race or ethnic group was self-reported.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma medication use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Inhaled corticosteroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Combination of fluticasone and salmeterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body-mass index &gt;=30</title>
          <description>The body-mass index is the weight in kilograms divided by the square of the height in meters.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>BMI &gt;=30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMI &lt;30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Conditions other than asthma</title>
          <description>These conditions were self-reported.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Gastroesophageal reflux disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No GER reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="182"/>
                    <measurement group_id="B3" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Former smoker</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Former Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="172"/>
                    <measurement group_id="B3" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health Care Visits</title>
          <description>Unscheduled health care visit for asthma in previous year</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Health care visit for asthma exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pulmonary function</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Participants with 20% post-diluent measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20% from post-diluent contraindicated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>potential Hydrogen (pH) monitoring</title>
          <description>Results of ambulatory measure of esophageal potential Hydrogen (pH) for 16 to 24 hours. Test were considered positive if pH was less than 4 for more than 5.8% of the total tiem, 8.2% of upright time, or 3.5% of supine time.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive result</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative result</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing result</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>%Predicted amount of air expired in the first second during a forced expiration pre broncho-dilator</title>
          <description>Percent of the predicted value for the amount of air expired in the first second during a forced expiratory maneuver (FEV1) based on gender, age and ethnicity that the measured value is.</description>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78" spread="15"/>
                    <measurement group_id="B2" value="76" spread="16"/>
                    <measurement group_id="B3" value="77" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age of onset of asthma</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17" spread="17"/>
                    <measurement group_id="B2" value="17" spread="16"/>
                    <measurement group_id="B3" value="17" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age of participants</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>at randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="13"/>
                    <measurement group_id="B2" value="42" spread="13"/>
                    <measurement group_id="B3" value="42" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at onset of asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17" spread="17"/>
                    <measurement group_id="B2" value="17" spread="16"/>
                    <measurement group_id="B3" value="17" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Asthma scores</title>
          <description>Asthma Control Score (ACS)ranges from 0 to 6, lower scores indicating better asthma control and 0.5 as the minimal clinically important difference; Asthma Symptom Utility Index (ASUI) score ranges from 0 to 1, higher scores indicating less severe asthma; Mini-Asthma Quality of Life Questionnaire (mini-AQLQ) score range from 1 to 7, higher scores indicating better quality of life and 0.5 as the minimal clinically important difference.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>ACQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9" spread="0.8"/>
                    <measurement group_id="B2" value="1.8" spread="0.8"/>
                    <measurement group_id="B3" value="1.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASUI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.74" spread="0.18"/>
                    <measurement group_id="B2" value="0.76" spread="0.15"/>
                    <measurement group_id="B3" value="0.75" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mini asthma quality of life questionnaire</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.7" spread="1.2"/>
                    <measurement group_id="B2" value="4.7" spread="1.2"/>
                    <measurement group_id="B3" value="4.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent change in FEV1 after bronchodilator</title>
          <description>The percent difference in FEV1 before and after using a bronchodilator (albuterol) divided by the value before bronchodilation.</description>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" spread="10"/>
                    <measurement group_id="B2" value="11" spread="16"/>
                    <measurement group_id="B3" value="11" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Exacerbation Components: &gt;=30% Drop in Peak Expiratory Flow on 2 Consecutive Days</title>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole</title>
            <description>40 mg of esomeprazole twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Exacerbation Components: &gt;=30% Drop in Peak Expiratory Flow on 2 Consecutive Days</title>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Rates were compared with incidence-rate ratios (IRR). The IRR and P values were estimated with the use of negative binomial regression models with robust variance estimates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <p_value_desc>P values are for the treatment effect of esomeprazole as compared with placebo.</p_value_desc>
            <method>Negative binomial regression</method>
            <param_type>Incidence-Rate Ratio</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exacerbation Components: Urgent Care Visit</title>
        <time_frame>Measured at Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole</title>
            <description>40 mg of esomeprazole twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Exacerbation Components: Urgent Care Visit</title>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Rates were compared with incidence-rate ratios (IRR). The IRR and P values were estimated with the use of negative binomial regression models with robust variance estimates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <p_value_desc>P values are for the treatment effect of esomeprazole as compared with placebo.</p_value_desc>
            <method>Negative binomial regression</method>
            <param_type>Incidence-Rate Ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Episodes of Poor Asthma Control (EPAC) From Diary Cards, According to Definition That Did Not Include Use of Beta-agonists as a Criterion</title>
        <description>Episodes of poor asthma control was defined as any one of the following: 2 consecutive days with a drop in peak flow &gt;=30% of baseline; urgent care for asthma; or new use of oral corticosteroids for asthma</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole</title>
            <description>40 mg of esomeprazole twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Episodes of Poor Asthma Control (EPAC) From Diary Cards, According to Definition That Did Not Include Use of Beta-agonists as a Criterion</title>
          <description>Episodes of poor asthma control was defined as any one of the following: 2 consecutive days with a drop in peak flow &gt;=30% of baseline; urgent care for asthma; or new use of oral corticosteroids for asthma</description>
          <units>events per person year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The rates of EPACs were compared using incidence-rate ratios (IRR). IRR and P value were estimated with the use of negative binomial regression models with robust variance estimates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <p_value_desc>P values are for the treatment effect of esomeprazole as compared with placebo.</p_value_desc>
            <method>Negative binomial regression</method>
            <param_type>Incidence-Rate Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exacerbation Components: New Use of Oral Corticosteroids</title>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole</title>
            <description>40 mg of esomeprazole twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Exacerbation Components: New Use of Oral Corticosteroids</title>
          <units>events per person year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Rates were compared with incidence-rate ratios (IRR). The IRR and P values were estimated with the use of negative binomial regression models with robust variance estimates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <p_value_desc>P values are for the treatment effect of esomeprazole as compared with placebo.</p_value_desc>
            <method>Negative binomial regression</method>
            <param_type>Incidence-Rate Ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Episodes, According to Definition That Included Increased Use of Beta-agonists</title>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole</title>
            <description>40 mg of esomeprazole twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Episodes, According to Definition That Included Increased Use of Beta-agonists</title>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Rates were compared with incidence-rate ratios (IRR). The IRR and P values were estimated with the use of negative binomial regression models with robust variance estimates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.87</p_value>
            <p_value_desc>P values are for the treatment effect of esomeprazole as compared with placebo.</p_value_desc>
            <method>Negative binomial regression</method>
            <param_type>Incidence-Rate Ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Rescue Medications</title>
        <description>Increase in the use of rescue meds by 4 or more uses on a particular day above the average uses during the run-in period.</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole</title>
            <description>40 mg of esomeprazole twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Rescue Medications</title>
          <description>Increase in the use of rescue meds by 4 or more uses on a particular day above the average uses during the run-in period.</description>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Incidence-rate ratios and P values were estimated with the use of negative binomial regression models with robust variance estimates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <p_value_desc>P values are for the treatment effect of esomeprazole as compared with placebo.</p_value_desc>
            <method>Negative binomial regression</method>
            <param_type>Incidence-Rate Ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night Awakening</title>
        <description>Rate of awakening at night because of asthma symptoms</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole</title>
            <description>40 mg of esomeprazole twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Night Awakening</title>
          <description>Rate of awakening at night because of asthma symptoms</description>
          <units>events per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Incidence-rate ratios and P values were estimated with the use of negative binomial regression models with robust variance estimates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.70</p_value>
            <p_value_desc>P values are for the treatment effect of esomeprazole as compared with placebo.</p_value_desc>
            <method>Negative binomial regression</method>
            <param_type>Incidence-Rate Ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Function: Change in Prebronchodilator FEV1</title>
        <description>Mean change in pre-bronchodilator FEV1 - forced expiratory volume in 1 second; a measure of pulmonary function. The treatment effect is the difference in the mean change in between the groups.</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <population>The analyses are based on data from 191 participants in the placebo group and 201 in the esomeprazole group, with the following exception: 41 participants in the placebo group and 37 in the esomeprazole group for measurement of 20% post-diluent baseline (PC20).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole</title>
            <description>40 mg of esomeprazole twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function: Change in Prebronchodilator FEV1</title>
          <description>Mean change in pre-bronchodilator FEV1 - forced expiratory volume in 1 second; a measure of pulmonary function. The treatment effect is the difference in the mean change in between the groups.</description>
          <population>The analyses are based on data from 191 participants in the placebo group and 201 in the esomeprazole group, with the following exception: 41 participants in the placebo group and 37 in the esomeprazole group for measurement of 20% post-diluent baseline (PC20).</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.06" upper_limit="0.01"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.04" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The treatment effect is the mean change in the Esomeprazole group - mean change in placebo group</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <p_value_desc>P values were calculated with the use of linear regression.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
            <estimate_desc>Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group, e.g. 0.00 - (-0.02) = -0.03 (rounding)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Function: Change in Prebronchodilator Forced Vital Capacity</title>
        <description>Pulmonary function measured by mean change in Prebronchodilator forced vital capacity from baseline to 24 weeks</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole</title>
            <description>40 mg of esomeprazole twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function: Change in Prebronchodilator Forced Vital Capacity</title>
          <description>Pulmonary function measured by mean change in Prebronchodilator forced vital capacity from baseline to 24 weeks</description>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-0.06" upper_limit="0.01"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.04" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
            <estimate_desc>Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Function: Change in Peak Flow Rate</title>
        <description>Mean change from baseline to 24 weeks in the peak flow rate - how forceful patient can blow out air</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole</title>
            <description>40 mg of esomeprazole twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function: Change in Peak Flow Rate</title>
          <description>Mean change from baseline to 24 weeks in the peak flow rate - how forceful patient can blow out air</description>
          <units>liters/min</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="-3.5" upper_limit="9.9"/>
                    <measurement group_id="O2" value="9.2" lower_limit="1.8" upper_limit="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>16.0</ci_upper_limit>
            <estimate_desc>Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Function: Change in PC20</title>
        <description>Mean Change in the dose of methacholine that results in a 20% drop in FEV1</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole</title>
            <description>40 mg of esomeprazole twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Function: Change in PC20</title>
          <description>Mean Change in the dose of methacholine that results in a 20% drop in FEV1</description>
          <units>mg/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.2" upper_limit="2.9"/>
                    <measurement group_id="O2" value="0.3" lower_limit="-1.4" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Regression, Linear</method>
            <param_type>Treatment Effect</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Juniper Asthma Control Score(JACQ)</title>
        <description>Mean change. Scores on the JACQ range from 0 to 6, with lower scores indicating better asthma control and 0.5 as the minimal clinically important difference.</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole</title>
            <description>40 mg of esomeprazole twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Juniper Asthma Control Score(JACQ)</title>
          <description>Mean change. Scores on the JACQ range from 0 to 6, with lower scores indicating better asthma control and 0.5 as the minimal clinically important difference.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-0.4" upper_limit="-0.2"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.3" upper_limit="-0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Regression, Linear</method>
            <param_type>Treatment Effect</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
            <estimate_desc>Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Asthma Symptom Utility Index (ASUI)</title>
        <description>Mean change. Scores on the ASUI range from 0 to 1, with higher scores indicating less severe asthma.</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole</title>
            <description>40 mg of esomeprazole twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Asthma Symptom Utility Index (ASUI)</title>
          <description>Mean change. Scores on the ASUI range from 0 to 1, with higher scores indicating less severe asthma.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.03" upper_limit="0.07"/>
                    <measurement group_id="O2" value="0.02" lower_limit="0.01" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
            <estimate_desc>Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ)</title>
        <description>Mean change. Scores on the Mini-Asthma Quality of Life Questionnaire (mini-AQLQ)range from 1 to 7, with higher scores indicating better quality of life and 0.5 as the minimal clinically important difference.</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole</title>
            <description>40 mg of esomeprazole twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ)</title>
          <description>Mean change. Scores on the Mini-Asthma Quality of Life Questionnaire (mini-AQLQ)range from 1 to 7, with higher scores indicating better quality of life and 0.5 as the minimal clinically important difference.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.2" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
            <estimate_desc>Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Medical Outcomes Study Short-Form 36 Score Quality of Life Score: Physical Component</title>
        <description>Mean change. Scores on the Medical Outcomes Study Short-Form 36 range from 1 to 100, with higher scores indicating better quality of life and 5 as the minimal clinically important difference.</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole</title>
            <description>40 mg of esomeprazole twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Medical Outcomes Study Short-Form 36 Score Quality of Life Score: Physical Component</title>
          <description>Mean change. Scores on the Medical Outcomes Study Short-Form 36 range from 1 to 100, with higher scores indicating better quality of life and 5 as the minimal clinically important difference.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.1" upper_limit="2.9"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.3" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
            <estimate_desc>Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Medical Outcomes Study Short-Form 36 Quality of Life Score: Mental Component</title>
        <description>Mean change. Scores on the Medical Outcomes Study Short-Form 36 range from 1 to 100, with higher scores indicating better quality of life and 5 as the minimal clinically important difference.</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole</title>
            <description>40 mg of esomeprazole twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Medical Outcomes Study Short-Form 36 Quality of Life Score: Mental Component</title>
          <description>Mean change. Scores on the Medical Outcomes Study Short-Form 36 range from 1 to 100, with higher scores indicating better quality of life and 5 as the minimal clinically important difference.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1.8" upper_limit="1.1"/>
                    <measurement group_id="O2" value="0.4" lower_limit="-0.5" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.78</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
            <estimate_desc>Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Gastric Symptoms: Gastroesophageal Reflux Disease Symptom Assessment Scale Score</title>
        <description>Mean change. The Gastroesophageal Reflux Disease Symptom Assessment Scale score ranges from 0 to 3, with lower numbers indicating less distress.</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole</title>
            <description>40 mg of esomeprazole twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gastric Symptoms: Gastroesophageal Reflux Disease Symptom Assessment Scale Score</title>
          <description>Mean change. The Gastroesophageal Reflux Disease Symptom Assessment Scale score ranges from 0 to 3, with lower numbers indicating less distress.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" lower_limit="-0.21" upper_limit="-0.12"/>
                    <measurement group_id="O2" value="-0.16" lower_limit="-0.20" upper_limit="-0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
            <estimate_desc>Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Gastric Symptoms: No. of Symptoms</title>
        <description>Mean change</description>
        <time_frame>Baseline to 24 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>40 mg of placebo twice daily</description>
          </group>
          <group group_id="O2">
            <title>Esomeprazole</title>
            <description>40 mg of esomeprazole twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Gastric Symptoms: No. of Symptoms</title>
          <description>Mean change</description>
          <units>symptoms</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" lower_limit="-2.1" upper_limit="-1.3"/>
                    <measurement group_id="O2" value="-1.9" lower_limit="-2.3" upper_limit="-1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.39</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
            <estimate_desc>Treatment effect is the difference in mean change in the esomeprazole group minus the mean change in the placebo group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>40 mg of placebo twice daily</description>
        </group>
        <group group_id="E2">
          <title>Esomeprazole</title>
          <description>40 mg of esomeprazole twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for possible cardiac ischemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="193"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization or emergency department visit for surgery, trauma, or other acute illness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="193"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma exacerbation requiring hospitalization</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="193"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Death from complications after surgery for endobronchial tumor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ellen Brown</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>443-287-3170</phone>
      <email>ala-acrc@jhsph.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

